Production of target‐specific recombinant human polyclonal antibodies in mammalian cells
- 4 April 2006
- journal article
- research article
- Published by Wiley in Biotechnology & Bioengineering
- Vol. 94 (2), 396-405
- https://doi.org/10.1002/bit.20865
Abstract
We describe the expression and consistent production of a first target-specific recombinant human polyclonal antibody. An anti-Rhesus D recombinant polyclonal antibody, Sym001, comprised of 25 unique human IgG1 antibodies, was produced by the novel Sympress expression technology. This strategy is based on site-specific integration of antibody genes in CHO cells, using the FRT/Flp-In recombinase system. This allows integration of the expression construct at the same genomic site in the host cells, thereby reducing genomic position effects. Different bioreactor batches of Sym001 displayed highly consistent manufacturing yield, antibody composition, binding potency, and functional activity. The results demonstrate that diverse recombinant human polyclonal antibody compositions can be reproducibly generated under conditions directly applicable to industrial manufacturing settings and present a first recombinant polyclonal antibody which could be used for treatment of hemolytic disease of the newborn and/or idiopathic thrombocytopenic purpura.This publication has 17 references indexed in Scilit:
- Recombinant polyclonal antibodies for cancer therapyJournal of Cellular Biochemistry, 2005
- Production of recombinant protein therapeutics in cultivated mammalian cellsNature Biotechnology, 2004
- Passive antibody therapy for infectious diseasesNature Reviews Microbiology, 2004
- A Comparison of thein Vitroandin VivoActivities of IgG and F(ab′)2 Fragments of a Mixture of Three Monoclonal Anti-Her-2 AntibodiesClinical Cancer Research, 2004
- The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer CellsCancer Research, 2004
- Deciphering antibody properties that lead to potent botulinum neurotoxin neutralizationMovement Disorders, 2004
- Generation and Production of Engineered AntibodiesMolecular Biotechnology, 2004
- Antibody Dependent Cell Mediated Cytotoxicity and Phagocytosis of Senescent Erythrocytes by Autologous Peripheral Blood Mononuclear CellsAutoimmunity, 2002
- Site-specific recombination: developments and applicationsCurrent Opinion in Biotechnology, 1994
- Recombinase-Mediated Gene Activation and Site-Specific Integration in Mammalian CellsScience, 1991